ERBB2 and breast cancer: Researchers had proved that miR-1296-5p could function as an inhibitor in gastric cancer by targeting cyclin-dependent kinase 6 and epidermal growth factor receptor [53], ERBB2-positive breast cancer by downregulating ERBB2 [17], in osteosarcoma through repressing notch receptor 2 expression [16].